TC
TRIL

TFS Capital’s Trillium Therapeutics Inc. TRIL Stock Holding History

TFS Capital’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,247
Closed -$58K – 924
2016
Q4 		$58K Buy
+10,247
New +$102K 0.02% 683
2016
Q3 		– Sell
-11,903
Closed -$107K – 1075
2016
Q2 		$107K Sell
11,903
-2,397
-17% -$24.9K 0.02% 846
2016
Q1 		$132K Buy
+14,300
New +$121K 0.02% 845

Other funds holding TRIL

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

TFS Capital's TRIL Position: Q1 2017 in Review

TFS Capital sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2017, closing a stake of 10,247 shares — an estimated $58K sold.

TFS Capital first reported a position in TRIL in Q1 2016 and held it in 3 quarters. The position peaked at $132K in Q1 2016. 22 funds tracked by Wall St. Rank hold TRIL as of Q1 2017.

  • TFS Capital reported no remaining Trillium Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 10,247 Trillium Therapeutics Inc. shares in Q1 2017, an estimated $58K.
  • TFS Capital first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 3 quarters.
  • TFS Capital's Trillium Therapeutics Inc. position peaked at $132K in Q1 2016.
  • 22 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.